KPTI Karyopharm Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KPTI

Price (delayed)

$9.08

Market cap

$205.78M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$16.16

Enterprise value

$345.49M

?
Relative Growth: Rel. Growth: 32
Relative Strength: Rel. Strength: 82
Relative Valuation: Rel. Valuation: 27
Relative Profitability: Rel. Profitability: 18

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related ...

Highlights
The company's gross profit rose by 6% YoY and by 3.6% QoQ
The revenue has grown by 6% YoY and by 3.5% from the previous quarter
The EPS has plunged by 100% YoY but it has grown by 10% from the previous quarter
The equity has contracted by 29% YoY but it has grown by 9% from the previous quarter
KPTI's debt is up by 24% YoY
Karyopharm Therapeutics's quick ratio has decreased by 16% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://karyopharm.com
Peers: MRK BMY ABT EXEL

Key stats

What are the main financial stats of KPTI

KPTI stock price

How has the Karyopharm Therapeutics stock price performed over time
Intraday
0.89%
1 week
-0.33%
1 month
-2.37%
1 year
109.22%
YTD
23.37%
QTD
63.02%

Financial performance

How have Karyopharm Therapeutics's revenue and profit performed over time
Revenue
$151.12M
Gross profit
$145.13M
Operating income
-$84.21M
Net income
-$194.97M
Gross margin
96%
Net margin
-129%
KPTI's net margin has plunged by 193% YoY but it is up by 3.9% from the previous quarter
KPTI's operating margin is up by 33% YoY and by 10% QoQ
KPTI's operating income is up by 29% YoY and by 7% QoQ
The company's gross profit rose by 6% YoY and by 3.6% QoQ

Price vs fundamentals

How does KPTI's price correlate with its fundamentals

Growth

What is Karyopharm Therapeutics's growth rate over time

Valuation

What is Karyopharm Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.29
The EPS has plunged by 100% YoY but it has grown by 10% from the previous quarter
The equity has contracted by 29% YoY but it has grown by 9% from the previous quarter
The P/S is 162% higher than the last 4 quarters average of 0.5 but 18% lower than the 5-year quarterly average of 1.6
The revenue has grown by 6% YoY and by 3.5% from the previous quarter

Efficiency

How efficient is Karyopharm Therapeutics business performance
The ROS has grown by 5% from the previous quarter
Karyopharm Therapeutics's return on invested capital has decreased by 2.8% QoQ

Dividends

What is KPTI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KPTI.

Financial health

How did Karyopharm Therapeutics financials performed over time
KPTI's total assets is 67% smaller than its total liabilities
KPTI's total assets is up by 21% since the previous quarter and by 2.9% year-on-year
KPTI's total liabilities is up by 19% YoY
KPTI's debt is 187% more than its equity
The equity has contracted by 29% YoY but it has grown by 9% from the previous quarter
KPTI's debt is up by 24% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.